

Electronic supplementary information for

Transfer of axial chirality through the nickel-catalyzed hydrocyanation of chiral allenes

Yuka Amako, Shigeru Arai*, and Atsushi Nishida

Graduate School of Pharmaceutical Sciences, Chiba University
1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan
E-mail: araisgr@chiba-u.jp

List of Contents

- A. General remarks (Page 2)
- B. Synthesis of optically active allenes (Page 2-4)
- C. General Procedure for Hydrocyanation (Page 5-8)
- D. Determination of absolute stereochemistry of (*R*)-**4a** and (*S*)-**4d** (Page 8)
- E. Examination of time course (Page 9)
- F. Examination of racemization (Page 9)
- G. References (Page 9)
- H. HPLC charts (Page 10-24)
- I. ^1H and ^{13}C NMR charts for all new compounds (page 25-)


A. General remarks

All reactions were performed with dry solvents and reagents were purified by the usual methods. Reactions were monitored by thin-layer chromatography carried out on 0.25 mm Merck silica gel plates (60F-254). Column chromatography was performed with silica gel (Fuji Silysia, PSQ-60B). IR spectra were recorded on a JASCO FT/IR-230 Fourier transform spectrophotometer. NMR spectra were recorded on JEOL JMN-ECS-400, ECP-400, ECA-600 and ECP-600 at 400 and 600 MHz for ¹H NMR and at 100 and 150 MHz for ¹³C NMR, with calibration using residual undeuterated solvent as an internal reference. Mass spectra were recorded using ESI mode with JEOL JMS-T100LP and APPI mode with Thermo Fisher Exactive. The enantiomeric excess was determined by HPLC analysis using JASCO HPLC LC-2000Plus series (PU-2089, CO-2065, UV-2075). Optical rotations were measured using JASCO P-1020 and P-2200 Polarimeter. X-ray crystal data were collected with Rigaku VariMax with RAPID diffractometer at -180±1 °C using filtered Cu-K α radiation.

B. Synthesis of optically active allenes

Optically active allenes were synthesized according to the reported procedure¹. Spectral data of (*R*)-3a,3d-g and 3k were identical to the literature data.²

(*R*)-(4,4-dimethylpenta-1,2-dien-1-yl)benzene ((*R*)-3a)³



HPLC conditions: Chiralcel OJ-H, hexane (100%), f: 0.5mL/min, tR: 10.2, 10.7 min (99% ee).


(*R*)-1-(4,4-dimethylpenta-1,2-dien-1-yl)-4-(trifluoromethyl)benzene ((*R*)-3b)

Colorless oil. ¹H NMR (CDCl₃, 600 MHz) δ: 1.13 (s, 9H), 5.64 (d, 1H, *J* = 6.0 Hz), 6.21 (d, 1H, *J* = 6.0 Hz), 7.37 (d, 2H, *J* = 7.8 Hz), 7.53 (d, 2H, *J* = 7.8 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ: 30.2, 32.9, 95.4, 107.4, 124.3 (q, *J* = 270.0 Hz), 125.5 (q, *J* = 4.4 Hz), 126.4, 128.5 (q, *J* = 31.7 Hz), 139.2, 203.5; IR (ATR) ν: 2961, 1949 cm⁻¹; HRMS (APPI) m/z calcd for C₁₄H₁₅F₃ [M]⁺ 240.1120, found 240.1116; [α]_D²⁵ = -234.30 (*c* = 1.24, CHCl₃, 98% ee); HPLC conditions: Chiralcel OJ-H, hexane (100%), f: 0.5 mL/min, tR: 9.1, 9.4 min (98% ee).

(*R*)-1-(4,4-dimethylpenta-1,2-dien-1-yl)-4-methoxybenzene ((*R*)-3c)


Colorless oil. ¹H NMR (CDCl₃, 400 MHz) δ: 1.11 (s, 9H), 3.79 (s, 3H), 5.55 (d, 1H, *J* = 5.6 Hz), 6.15 (d, 1H, *J* = 5.6 Hz), 6.84 (d, 2H, *J* = 8.4 Hz), 7.21 (d, 2H, *J* = 8.4 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ: 30.3, 32.7, 55.3, 95.6, 106.9, 114.1, 127.4, 127.6, 158.5, 201.7; IR (ATR) ν: 2057, 1947 cm⁻¹; HRMS (APPI) m/z calcd for C₁₄H₁₉O [M+H]⁺ 203.1430, found 240.1425; [α]_D²⁵ = -248.2 (*c* = 1.02, CHCl₃, 88% ee); HPLC conditions: Chiralcel OJ-H, hexane/*i*-PrOH = 99:1, f: 0.5 mL/min, tR: 12.7, 14.5 min (88% ee).

(R)-(3-cyclohexylpropa-1,2-dien-1-yl)benzene ((R)-3d)¹




HPLC conditions: Chiralcel IB, hexane (100%), f: 0.5 mL/min, 9.6, 10.6 min (97% ee).

(R)-1-(3-cyclohexylpropa-1,2-dien-1-yl)-4-(trifluoromethyl)benzene ((R)-3e)




$[\alpha]_D^{24} = -300.1$ ($c = 1.12$, CHCl₃, 98% ee); HPLC conditions: Chiralcel OD-H, hexane (100%), f: 1.0 mL/min, tR: 5.4, 6.0 min (97% ee)

(R)-1-(3-cyclohexylpropa-1,2-dien-1-yl)-4-methoxybenzene ((R)-3f)




$[\alpha]_D^{26} = -268.4$ ($c = 1.26$, CHCl₃, 85% ee); HPLC conditions: Chiralcel OD-H, hexane/*i*-PrOH = 99:1, f: 1.0 mL/min, tR: 4.7, 5.1 min (85% ee).

(R)-1-bromo-4-(3-cyclohexylpropa-1,2-dien-1-yl)benzene ((R)-3g)




$[\alpha]_D^{24} = -306.9$ ($c = 1.28$, CHCl₃, 98% ee); HPLC conditions: Chiraldak IB, hexane (100%), f: 0.5 mL/min, tR: 9.1, 11.4 min (98% ee)

(R)-1-(3-cyclohexylpropa-1,2-dien-1-yl)-3-(trifluoromethyl)benzene ((R)-3h)



Colorless oil. ¹H NMR (CDCl₃, 400 MHz) δ : 1.16-1.36 (m, 5H), 1.63-1.67 (m, 1H), 1.73-1.76 (m, 2H), 1.83-1.86 (m, 2H), 2.12-2.21 (m, 1H), 5.63 (dd, 1H, *J* = 6.4, 6.4 Hz), 6.18 (dd, 1H, *J* = 6.4, 3.2 Hz), 7.37-7.47 (m, 3H), 7.52 (s, 1H); ¹³C NMR (CDCl₃, 150 MHz) δ : 25.97, 26.04, 33.1, 37.5, 94.6, 101.8, 123.0 (*J* = 2.9 Hz), 123.1 (*J* = 2.9 Hz), 124.2 (*J* = 271.4 Hz), 128.9, 129.5, 131.0 (*J* = 33.0 Hz), 136.3, 204.6; IR (ATR) ν : 2925, 2852, 1948 cm⁻¹; HRMS (APPI) m/z calcd for C₁₆H₁₇F₃ [M]⁺ 266.1277, found 266.1269; $[\alpha]_D^{24} = -286.5$ ($c = 1.12$, CHCl₃, 97% ee); HPLC conditions: Chiralcel OD-H, hexane (100%), f: 0.5 mL/min, tR: 9.1, 9.8 min (97% ee).


(R)-1-(3-cyclohexylpropa-1,2-dien-1-yl)-3-methoxybenzene ((R)-3i)




Colorless oil. ¹H NMR (CDCl₃, 400 MHz) δ : 1.13-1.35 (m, 5H), 1.62-1.65 (m, 1H), 1.71-1.76 (m, 2H), 1.82-1.85 (m, 2H), 2.09-2.17 (m, 1H), 3.80 (s, 3H), 5.65 (dd, 1H, *J* = 6.4, 6.4 Hz), 6.12 (dd, 1H, *J* = 6.4, 2.8 Hz), 6.73 (dd, 1H, *J* = 8.0, 2.4 Hz), 6.85-6.89 (m, 2H), 7.20 (dd, 1H, *J* = 8.0 Hz); ¹³C NMR (CDCl₃, 100 MHz) δ : 26.0, 26.0, 26.1, 33.05, 33.15, 37.5, 55.0, 95.3, 101.0, 111.6, 112.3, 119.1, 129.4, 136.7, 159.8, 204.1; IR (ATR) ν : 2921, 2849, 1946 cm⁻¹; HRMS (APPI) m/z calcd for

$C_{16}H_{20}O$ $[M]^+$ 228.1509, found 228.1503; $[\alpha]_D^{24} = -327.7$ ($c = 0.97$, $CHCl_3$, 94% ee); HPLC conditions: Chiralcel OJ-H, hexane/*i*-PrOH = 99:1, f: 0.5 mL/min, tR: 11.5, 12.4 min (94% ee)


(*R*)-2-(3-cyclohexylpropa-1,2-dien-1-yl)naphthalene ((*R*)-3j)


Colorless solid. 1H NMR ($CDCl_3$, 400 MHz) δ : 1.16-1.37 (m, 5H), 1.63-1.66 (m, 1H), 1.73-1.1.78 (m, 2H), 1.86-1.89 (m, 2H), 2.13-2.22 (m, 1H), 5.64 (dd, 1H, $J = 6.4$ Hz), 6.34 (dd, 1H, $J = 6.4, 4.8$ Hz), 7.26-7.46 (m, 2H), 7.50 (dd, 1H, $J = 8.8, 2.0$ Hz), 7.64 (s, 1H), 7.75-7.79 (m, 3H); ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 26.0, 26.1, 33.1, 33.2, 37.6, 95.8, 101.3, 124.5, 125.1, 125.4, 126.1, 127.6, 127.7, 128.1, 132.5, 132.7, 133.7, 204.7; IR (ATR) ν : 2922, 2849, 1946 cm^{-1} ; HRMS (APPI) m/z calcd for $C_{19}H_{20}$ $[M]^+$ 248.1560, found 248.1554; mp. 42-43 °C; $[\alpha]_D^{26} = -323.8$ ($c = 1.03$, $CHCl_3$, 96% ee); HPLC conditions: Chiralcel AS-H, hexane (100%), f: 0.5 mL/min, tR: 9.9, 10.2 min, (96% ee).


(*R*)-deca-1,2-dien-1-ylbenzene ((*R*)-3k)


 $[\alpha]_D^{24} = -237.9$ ($c = 1.28$, $CHCl_3$, 97% ee); HPLC conditions: Chiralcel OD-H, hexane (100%), f: 0.5 mL/min, tR: 10.2, 10.7 min (97% ee).

(*R*)-1-(deca-1,2-dien-1-yl)-4-(trifluoromethyl)benzene ((*R*)-3l)


Colorless oil. 1H NMR ($CDCl_3$, 600 MHz) δ : 0.87 (t, 3H, $J = 7.2$ Hz), 1.24-1.38 (m, 8H), 1.45-1.51 (m, 2H), 2.14 (ddt, 2H, $J = 7.2, 7.2, 3.0$ Hz), 5.63 (dt, 1H, $J = 7.2, 7.2$ Hz), 6.14 (dt, 1H, $J = 7.2, 3.0$ Hz), 7.37 (d, 2H, $J = 7.8$ Hz), 7.53 (d, 2H, $J = 7.8$ Hz); ^{13}C NMR ($CDCl_3$, 100 MHz) δ : 14.0, 22.6, 28.5, 29.09, 29.09, 29.14, 31.9, 93.8, 95.7, 124.3 (q, $J = 270$ Hz), 125.4 (q, $J = 3.8$ Hz), 126.6, 128.5 (q, $J = 32$ Hz), 139.2, 206.1; IR (ATR) ν : 2925, 2855, 1949 cm^{-1} ; HRMS (APPI) m/z calcd for $C_{17}H_{21}F_3$ $[M]^+$ 282.1590, found 282.1590; $[\alpha]_D^{26} = -190.6$ ($c = 1.22$, $CHCl_3$, 96% ee); HPLC conditions: Chiralcel OD-H, hexane (100%), f: 0.5 mL/min, tR: 8.0, 8.6 min (96% ee).


(*R*)-N-(4,4-dimethylpent-2-yn-1-yl)-4-methyl-N-(4-phenylbuta-2,3-dien-1-yl)benzenesulfonamide ((*R*)-6)


Colorless solid. 1H NMR ($CDCl_3$, 400 MHz) δ : 0.87 (s, 9H), 2.41 (s, 3H), 3.92 (ddd, 1H, $J = 14.0, 7.2, 2.0$ Hz), 4.01 (dd, 1H, $J = 14.0, 6.8, 2.8$ Hz), 4.21 (s, 2H), 5.49 (ddd, 1H, $J = 7.2, 6.8, 6.8$ Hz), 6.21 (ddd, 1H, $J = 6.8, 2.8, 2.0$ Hz), 7.18-7.21 (m, 1H), 7.25-7.31 (m, 6H), 7.74 (d, 2H, $J = 7.6$ Hz); ^{13}C NMR ($CDCl_3$, 150 MHz) δ : 21.4, 27.0, 30.4, 36.6, 45.5, 70.4, 90.4, 94.9, 96.1, 126.9, 127.3, 127.7, 128.6, 129.6, 133.5, 136.2, 143.3, 206.7; IR (ATR) ν : 2969, 1952, 1348, 1160 cm^{-1} ; HRMS (ESI) m/z calcd for $C_{24}H_{27}NNaO_2S$ $[M+Na]^+$ 416.1660, found 416.1663; mp. 60-61 °C; $[\alpha]_D^{25} = -171.2$ ($c = 0.99$, $CHCl_3$, 70% ee); HPLC conditions: Chiraldak IA, hexane/*i*-PrOH = 90:10, f: 1.0 mL/min, tR: 6.0, 6.5 min (92% ee).


C. General Procedure for Hydrocyanation

A solution of PMePh₂ (14 μ L, 0.075 mmol) and Ni[P(OPh)₃]₄ (24.4 mg, 0.019 mmol) in toluene (190 μ L) was heated under Ar atmosphere at 100 °C for 10 min. After cooling to room temperature, a solution of allene (0.19 mmol) and acetonecyanohydrin (84 μ L, 0.94 mmol) in toluene (280 μ L) were added and heated until the allene was disappeared. The reaction mixture was filtrated through Celite®, concentrated under vacuo and purified by column chromatography. Spectral data of (*R*)-**3a**, (*S*)-**3d-g** and **3k** were identical to the literature data.²


(*R,E*)-2-(*tert*-butyl)-4-phenylbut-3-enenitrile ((*R*)-**4a**)




(*R,E*)-2-(*tert*-butyl)-4-(4-(trifluoromethyl)phenyl)but-3-enenitrile ((*R*)-**4b**)



(*R,E*)-2-(*tert*-butyl)-4-(4-methoxyphenyl)but-3-enenitrile ((*R*)-**4c**)




(*S,E*)-2-cyclohexyl-4-phenylbut-3-enenitrile ((*S*)-**4d**)



*Measured after recrystallization from hexane.

(*S,E*)-2-cyclohexyl-4-(4-(trifluoromethyl)phenyl)but-3-enenitrile ((*S*)-**4e**)




(S,E)-2-cyclohexyl-4-(4-methoxyphenyl)but-3-enenitrile ((S)-4f)

$[\alpha]_D^{25} = +10.73$ ($c = 1.12$, CHCl₃, 65% ee); HPLC conditions: Chiraldak IB, hexane/i-PrOH = 98:2, f: 1.0 mL/min, tR: 8.1, 8.5 min (65% ee).

(S,E)-4-(4-bromophenyl)-2-cyclohexylbut-3-enenitrile ((S)-4g)

$[\alpha]_D^{25} = +6.84$ ($c = 0.51$, CHCl₃)
Ee was determined after converted to (S)-S1 (Scheme S1).

Scheme S1. Reduction of (S)-4g



(S,E)-4-(4-bromophenyl)-2-cyclohexylbut-3-en-1-ol ((S)-S1)

Colorless solid. ¹H NMR (CDCl₃, 400 MHz) δ: 0.94-1.35 (m, 6H), 1.40-1.49 (m, 1H), 1.63-1.72 (m, 5H), 2.17-2.24 (m, 1H), 3.57 (dd, 1H, $J = 10.0, 9.2$ Hz), 3.75-3.80 (m, 1H), 6.05 (dd, 1H, $J = 16.0, 10.0$ Hz), 6.40 (d, 1H, $J = 16.0$ Hz), 7.24 (d, 2H, $J = 8.4$ Hz), 7.43 (d, 2H, $J = 8.4$ Hz); ¹³C NMR (CDCl₃, 100 MHz) δ: 26.37, 26.40, 26.5, 30.4, 31.2, 38.9, 52.2, 63.8, 120.9, 127.6, 131.2, 131.6, 131.8, 136.0; IR (ATR) ν: 3289, 2922, 2849 cm⁻¹; HRMS (APPI) m/z calcd for C₁₆H₂₂OBr [M+H]⁺ 309.0849, found 309.0861; mp. 97-98 °C; $[\alpha]_D^{23} = +8.81$ ($c = 0.71$, CHCl₃, 66% ee); HPLC conditions: Chiraleel OJ-H, hexane/i-PrOH = 95:5, f: 1.0 mL/min, tR: 9.4, 10.6 min (66% ee).

(S,E)-2-cyclohexyl-4-(3-(trifluoromethyl)phenyl)but-3-enenitrile ((S)-4h)


Colorless oil. ¹H NMR (CDCl₃, 400 MHz) δ: 1.13-1.29 (m, 5H), 1.68-1.90 (m, 6H), 3.33 (dd, 1H, $J = 6.4, 6.4$ Hz), 6.11 (dd, 1H, $J = 16.0, 6.4$ Hz), 6.74 (d, 1H, $J = 16.0$ Hz), 7.45 (dd, 1H, $J = 7.6, 7.6$ Hz), 7.51-7.54 (m, 2H), 7.61 (s, 1H); ¹³C NMR (CDCl₃, 100 MHz) δ: 25.77, 25.79, 25.9, 29.6, 31.0, 40.8, 41.1, 118.0, 123.0 (q, $J = 2.9$ Hz), 124.0 (q, $J = 271.2$ Hz), 124.2, 124.7 (q, $J = 2.7$ Hz), 129.2, 129.8, 131.1 (q, 32.6 Hz), 132.5, 136.5; IR (ATR) ν: 2928, 2855, 2241 cm⁻¹; HRMS (APPI) m/z calcd for C₁₇H₁₈F₃N [M]⁺ 293.1386, found 293.1379; $[\alpha]_D^{25} = +7.85$ ($c = 0.94$, CHCl₃, 80% ee); HPLC conditions: Chiraldak IB, hexane/i-PrOH = 99:1, f: 1.0 mL/min, tR: 9.0, 10.0 min (80% ee).

(S,E)-2-cyclohexyl-4-(3-methoxyphenyl)but-3-enenitrile ((S)-4i)

Colorless oil. ¹H NMR (CDCl₃, 400 MHz) δ: 1.13-1.29 (m, 5H), 1.67-1.81 (m, 2H), 1.78-1.91 (m, 4H), 3.30 (dd, 1H, $J = 6.4, 6.4$ Hz), 3.82 (s, 3H), 6.03 (dd, 1H, $J = 16.0, 6.4$ Hz), 6.67 (d, 1H, $J = 16.0$ Hz), 6.83 (d, 1H, $J = 8.0$ Hz), 6.91 (s, 1H), 6.97 (d, 1H, $J = 8.0$ Hz).


Hz), 7.25 (dd, 1H, J = 8.0, 8.0 Hz); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 25.8, 25.8, 25.9, 29.6, 30.9, 40.8, 41.1, 55.2, 111.9, 113.7, 119.0, 119.3, 122.4, 129.6, 133.8, 137.2, 159.8; IR (ATR) ν : 2926, 2853, 2239 cm^{-1} ; HRMS (APPI) m/z calcd for $\text{C}_{17}\text{H}_{21}\text{NO} [\text{M}]^+$ 255.1618, found 255.1611; $[\alpha]_D^{25} = +6.24$ ($c = 0.79$, CHCl_3 , 74% ee); HPLC conditions: Chiralpak IB, hexane/*i*-PrOH = 98:2, f: 1.0 mL/min, tR: 9.3, 15.9 min (74% ee).

(*S,E*)-2-cyclohexyl-4-(naphthalen-2-yl)but-3-enenitrile ((*S*)-4j)




Ee was determined after converted to the corresponding alcohol (*S*)-S2 (Scheme S2).


Scheme S2. Reduction of (S)-4j




(*S,E*)-2-cyclohexyl-4-(naphthalen-2-yl)but-3-en-1-ol ((*S*)-S2)



(*S,E*)-2-styryloctanenitrile ((*S*)-4k)



(S,E)-2-(4-(trifluoromethyl)styryl)nonanenitrile ((S)-4l)



1H, $J = 16.0, 6.4$ Hz), 6.78 (d, 1H, $J = 16.0$ Hz), 7.48 (d, 2H, 8.0 Hz), 7.59 (d, 2H, $J = 8.0$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 14.0, 22.5, 26.8, 28.91, 28.93, 31.6, 33.1, 34.4, 199.8, 124.0 (q, $J = 270.2$), 125.6 (q, $J = 3.8$ Hz), 126.0, 126.7, 130.0 (q, $J = 32.6$ Hz), 131.8, 139.2; IR (ATR) ν : 2928, 2858, 2242 cm^{-1} ; HRMS (APPI) m/z calcd for $\text{C}_{18}\text{H}_{22}\text{F}_3\text{N}$ [M] $^+$ 309.1699, found 309.1694; $[\alpha]_D^{25} = +6.8$ ($c = 1.15$, CHCl_3 , 63% ee); HPLC conditions*: Chiralcel AD-H, hexane/*i*-PrOH = 99:1, f: 1.0 mL/min, tR: 10.3, 11.3 min (63% ee).

*Racemic sample was separated by using Chiralcpak IA better than Chiralcel AD-H, however chiral sample could not be separated very well by using Chiralcpak IA. Both charts are shown in page xx.


(*E*)-3,3-dimethyl-2-((*S*)-4-((*E*)-styryl)-1-tosylpyrrolidin-3-ylidene)butanenitrile ((*S*)-7)

Colorless solid. ^1H NMR (CDCl_3 , 600 MHz) δ : 1.21 (s, 9H), 2.45 (s, 3H), 3.16 (dd, 1H, $J = 11.4$, 6.0 Hz), 3.51 (d, 1H, $J = 9.6$ Hz), 3.78 (dd, 1H, 7.8, 6.0 Hz), 3.96 (d, 1H, $J = 16.2$ Hz), 4.33 (d, 1H, $J = 16.2$ Hz), 5.99 (dd, 1H, $J = 16.2, 7.8$ Hz), 6.57 (d, 1H, $J = 16.2$ Hz), 7.23-7.25 (m, 1H), 7.30-7.31 (m, 4H), 7.37 (d, 2H, $J = 7.8$ Hz), 7.73 (d, 2H, $J = 7.8$ Hz); ^{13}C NMR (CDCl_3 , 100 MHz) δ : 21.6, 29.6, 35.4, 49.5, 50.0, 51.8, 117.1, 120.0, 125.9, 126.6, 127.8, 128.5, 129.9, 130.0, 132.0, 132.4, 136.3, 144.3, 153.3; IR (ATR) ν : 2968, 2212, 1348, 1161 cm^{-1} ; HRMS (ESI) m/z calcd for $\text{C}_{25}\text{H}_{28}\text{N}_2\text{NaO}_2\text{S}$ [M+Na] $^+$ 443.1769, found 443.1771; mp. 123-124 °C; $[\alpha]_D^{25} = -59.6$ ($c = 0.51$, CHCl_3 , 42% ee); HPLC conditions: Chiralpak IB, hexane/*i*-PrOH = 75:25, f: 1.0 mL/min, tR: 6.6, 8.1 min (64% ee).

D. Determination of absolute stereochemistry of (*R*)-4a and (*S*)-4d


Absolute stereochemistry of (*R*)-4a was determined after conversion to (*R*)-S3 and comparing specific optical rotation with that of reported (*S*)-S3⁴ (Scheme S3).

Scheme S3. Reduction of (*R*)-4a



Absolute stereochemistry of (*S*)-4d was determined after conversion to (*S*)-S4 and comparing specific optical rotation with that of reported (*R*)-S4⁵ (Scheme S4).

Scheme S4. Reduction of (*S*)-4d



E. Examination of time course

A solution of phosphorous ligand and Ni[P(OPh)₃]₄ (33.7 mg, 0.028 mmol) in toluene (285 µL) was heated under Ar atmosphere at 100 °C for 10 min. After cooling to room temperature, a solution of allene (0.28 mmol), acetonecyanohydrin (52 µL, 0.56 mmol) and 4-methoxybiphenyl (10.4 mg, 0.056 mmol) as an internal standard in toluene (420 µL) were added and heated. The sample was taken from the reaction mixture via syringe in a specific time, filtrated through Celite® and concentrated under vacuo. The yield was calculated according to the ¹H NMR spectra and the ee was determined by HPLC after purification by preparative TLC.

Table S1. Time course profiling

time (min)	(R)-3a y. (%) (ee %)	(R)-4a y. (%) (ee %)	(R)-3d y. (%) (ee %)	(S)-4d y. (%) (ee %)	(R)-3k y. (%) (ee %)	(S)-4k y. (%) (ee %)
0	100 (99)	0 (-)	100 (96)	0 (-)	100 (97)	0 (-)
2	-	-	90 (94)	2 (78)	71 (92)	15 (52)
5	55 (96)	28 (98)	69 (91)	18 (78)	0 (-)	74 (48)
15	41 (92)	44 (98)	37 (80)	47 (74)	-	-
20	20 (92)	59 (98)	9 (80)	67 (74)	-	-
30	4 (80)	84 (97)	0 (-)	76 (72)	-	-
45	0 (-)	91 (97)	-	-	-	-

F. Examination of racemization

A solution of phosphorous ligand and Ni[P(OPh)₃]₄ (12.2 mg, 0.0094 mmol) in toluene (100 µL) was heated under Ar atmosphere at 100 °C for 10 min. After cooling to room temperature, a solution of (R)-3e (25.0 mg, 0.094 mmol) in toluene (135 µL) were added and heated for 6 h. The reaction mixture was filtrated through Celite®, concentrated under vacuo and purified by column chromatography to provide 3e (6.0 mg, 0.023 mmol, 24%, 2% ee) and 8 (3.8 mg, 0.014 mmol, 15%).

(E)-1-(3-cyclohexyldieneprop-1-en-1-yl)-4-(trifluoromethyl)benzene (8)

Colorless solid. ¹H NMR (CDCl₃, 400 MHz) δ: 1.61 (bs, 6H), 2.22 (bs, 2 H), 2.41 (bs, 2H), 5.97 (d, 1H, *J* = 10.8 Hz), 6.46 (d, 1H, *J* = 15.6 Hz), 7.14 (dd, 1H, *J* = 15.6, 10.8 Hz), 7.46 (d, 2H, *J* = 8.4 Hz), 7.53 (d, 2H, *J* = 8.4 Hz); ¹³C NMR (CDCl₃, 150 MHz) δ: 26.7, 27.9, 28.6, 29.7, 37.6, 122.0, 123.3 (*J* = 270 Hz), 125.5 (*J* = 4.2 Hz), 126.0, 127.3, 128.2, 128.5 (*J* = 30.3 Hz), 141.7, 147.0; IR (ATR) ν: 2927, 2852, 1638, 1608, 1321 cm⁻¹; HRMS (APPI) m/z calcd for C₁₆H₁₇F₃ [M]⁺ 266.1277, found 266.1277; mp. 63-64 °C.



G. References

- 1) Lu, R., Ye, J. Cao, T., Chen, B., Fan, W. Lin, W., Liu, J., Luo, H., Miao, B., Ni, S., Tang, X., Wang, N., Wang, Y., Xie, X., Yu, Q., Yuan, W., Zhang, W., Zhu, C., Ma, S. *Org. Lett.* **2013**, 15, 2254-2257.
- 2) Arai, S., Hori, H., Amako, Y., Nishida, A. **2015**, *Chem. Commun.* **51**, 7493-7496.
- 3) Elsevier, C. J., Vermeer, P. *J. Org. Chem.* **1989**, **54**, 3726–3730.

- 4) Spino, C., Gund, V. G., Nadeau, S. *J. Comb. Chem.* **2005**, 7, 345-352.
- 5) Kim, H., MacMillan, D. W. C. *J. Am. Chem. Soc.* **2008**, 130, 398-399.



H. HPLC Charts

(*R*)-(4,4-dimethylpenta-1,2-dien-1-yl)benzene ((*R*)-3a)





#	tR (min)	面積	面積 %	#	tR (min)	面積	面積 %
1	10.208	116539	49.457	1	10.258	77294	0.641
2	10.608	119098	50.543	2	10.657	11988380	99.359

(*R*)-1-(4,4-dimethylpenta-1,2-dien-1-yl)-4-(trifluoromethyl)benzene ((*R*)-3b)





#	tR (min)	面積	面積 %	#	tR (min)	面積	面積 %
1	9.067	2515360	48.043	1	9.108	26240	0.944
2	9.350	2720324	51.957	2	9.400	2753971	99.056

(R)-1-(4,4-dimethylpenta-1,2-dien-1-yl)-4-methoxybenzene ((R)-3c)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	12.925	4160965	49.964	1	12.708	463934	5.945
2	14.908	4166903	50.036	2	14.525	7339823	94.055

(R)-(3-cyclohexylpropa-1,2-dien-1-yl)benzene ((R)-3d)





#	tR	面積	面積%	#	tR	面積	面積%
1	10.067	168862	50.756	1	9.600	10874658	98.672
2	11.133	163830	49.244	2	10.633	146395	1.328

(R)-1-(3-cyclohexylpropa-1,2-dien-1-yl)-4-(trifluoromethyl)benzene ((R)-3e)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	4.133	140906	50.655	1	4.217	13800	1.009
2	4.467	137263	49.345	2	4.475	1354521	98.991

(R)-1-(3-cyclohexylpropa-1,2-dien-1-yl)-4-methoxybenzene ((R)-3f)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	4.808	96076	51.637	1	4.683	70987	7.397
2	5.292	89986	48.363	2	5.083	888631	92.603

(R)-1-bromo-4-(3-cyclohexylpropa-1,2-dien-1-yl)benzene ((R)-3g)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	9.158	519146	50.222	1	9.058	11288	0.766
2	11.600	514558	49.778	2	11.433	1461677	99.234

(R)-1-(3-cyclohexylpropa-1,2-dien-1-yl)-3-(trifluoromethyl)benzene ((R)-3h)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	8.158	113154	49.820	1	9.142	334070	98.504
2	8.642	113971	50.180	2	9.767	5073	1.496

(R)-1-(3-cyclohexylpropa-1,2-dien-1-yl)-3-methoxybenzene ((R)-3i)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	11.433	738457	51.554	1	11.467	2360718	96.908
2	12.483	693931	48.446	2	12.400	75313	3.092

(R)-2-(3-cyclohexylpropa-1,2-dien-1-yl)naphthalene ((R)-3j)





#	tR	面積	面積%	#	tR	面積	面積%
1	9.783	1382910	48.441	1	9.933	22318	2.160
2	10.200	1471900	51.559	2	10.342	1011019	97.840

(R)-deca-1,2-dien-1-ylbenzene ((R)-3k)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	6.050	584762	49.946	1	5.450	1828575	98.488
2	6.483	586021	50.054	2	6.000	28071	1.512

(R)-1-(deca-1,2-dien-1-yl)-4-(trifluoromethyl)benzene ((R)-3l)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	8.158	797619	50.049	1	8.042	10438	1.977
2	8.800	796053	49.951	2	8.575	517630	98.023

(R)-N-(4,4-dimethylpent-2-yn-1-yl)-4-methyl-N-(4-phenylbuta-2,3-dien-1-yl)benzenesulfonamide ((R)-6)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	6.000	71568	50.937	1	6.042	12209	3.780
2	6.442	68935	49.063	2	6.492	310814	96.220

(R,E)-2-(tert-butyl)-4-phenylbut-3-enenitrile ((R)-4a)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	9.900	81652	50.342	1	9.417	6681	1.462
2	10.833	80542	49.658	2	10.050	450198	98.538

(*R,E*)-2-(*tert*-butyl)-4-(4-(trifluoromethyl)phenyl)but-3-enenitrile ((*R*)-4b)





#	tR	面積	面積%	#	tR	面積	面積%
1	15.625	299721	50.014	1	15.200	2897462	96.821
2	17.983	299557	49.986	2	18.775	95140	3.179

(*R,E*)-2-(*tert*-butyl)-4-(4-methoxyphenyl)but-3-enenitrile ((*R*)-4c)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	9.167	86087	49.281	1	9.117	468366	92.137
2	9.883	88600	50.719	2	9.817	39971	7.863

(S,E)-2-cyclohexyl-4-phenylbut-3-enenitrile ((S)-4d)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	11.092	304346	50.188	1	10.333	30546	10.788
2	11.975	302069	49.812	2	11.167	252609	89.212

(S,E)-2-cyclohexyl-4-(4-(trifluoromethyl)phenyl)but-3-enenitrile ((R)-4e)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	8.267	190719	50.214	1	8.358	414668	90.782
2	8.667	189094	49.786	2	8.792	42106	9.218

(S,E)-2-cyclohexyl-4-(4-methoxyphenyl)but-3-enenitrile ((S)-4f)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	8.483	32362	49.540	1	8.142	613972	82.734
2	8.808	32963	50.460	2	8.492	128132	17.266

(S,E)-4-(4-bromophenyl)-2-cyclohexylbut-3-en-1-ol ((S)-S1)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	9.433	925379	50.261	1	9.442	16612	17.189
2	10.550	915767	49.739	2	10.600	80028	82.811

(S,E)-2-cyclohexyl-4-(3-(trifluoromethyl)phenyl)but-3-enenitrile ((S)-4h)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	9.067	2195016	50.015	1	8.950	69742	9.683
2	10.167	2193729	49.985	2	10.000	650499	90.317

(S,E)-2-cyclohexyl-4-(3-methoxyphenyl)but-3-enenitrile ((S)-4i)





#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	9.567	231967	50.007	1	9.267	56560	12.859
2	15.292	231906	49.993	2	15.875	383276	87.141

(S,E)-2-cyclohexyl-4-(naphthalen-2-yl)but-3-en-1-ol ((S)-S2)




#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	12.800	355799	50.161	1	12.483	16634	13.962
2	16.250	353519	49.839	2	15.883	102500	86.038

(S,E)-2-styryloctanenitrile ((S)-4k)




#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	9.467	70132	49.967	1	9.500	63612	26.459
2	9.833	70224	50.033	2	9.742	176805	73.541


(S,E)-2-(4-(trifluoromethyl)styryl)nonanenitrile ((S)-4l)





Chiralcel AD-H



Chiraldpak IA







(E)-3,3-dimethyl-2-((S)-4-((E)-styryl)-1-tosylpyrrolidin-3-ylidene)butanenitrile ((S)-7)







#	tR (min)	面積	面積%	#	tR (min)	面積	面積%
1	6.608	446340	49.869	1	6.558	8132999	82.694
2	8.050	448681	50.131	2	8.107	1702068	17.306

I. ¹H and ¹³C NMR charts for all new compounds













Single pulse decoupled proton NMR
D:\DEA\NMR\rf\...americano\previous data\2018.06\GSVA-180627-20-40_Proton_R-1-1.jcf




Single pulse decoupled carbon NMR
D:\DEA\NMR\rf\...americano\previous data\2018.07\GSVA-180714-20-40_Carbon_R-1-1.jcf










Single pulse decoupled proton NMR
D:\DEA\try\try_f\...americano\previous data\2016.09\GSVA-160817-27-48_Proton_1-1.jdf







Single pulse decoupled proton NMR
D:\DEA\try\try_f\...americano\previous data\2016.09\GSVA-160913-27-73_Carbon-1-1.jdf


























Single pulse decoupled proton NMR
D:\DEA\NMR\f_f_\semisolid\previous data\2016.10\GSVA-161007-22-14_Proton_3h-1.jdf



Single pulse decoupled carbon NMR
D:\DEA\NMR\f_f_\semisolid\previous data\2016.12\GSVA-161202-Br-OH_Carbon-1.jdf

